News for GT Biopharma, Inc. (GTBP)

GT Biopharma, trading under the ticker GTBP, has successfully completed the dosing of Cohort 1 in its Phase 1 dose escalation trial for GTB-3650. This study is

GT Biopharma (GTBP) successfully completes Cohort 1 of its Phase 1 trial for GTB-3650 without safety concerns. The trial shows early signs of increased

GT Biopharma (GTBP) has made a significant change to its leadership team with the appointment of Andrew Ritter to its Board of Directors. Ritter steps in to fil

SAN FRANCISCO, CALIFORNIA, May 15, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the ”œCompany”) ( GTBP), a clinical stage immuno-oncology company focused o

GT Biopharma, identified with the ticker GTBP, has made a significant change to its Board of Directors. The company welcomes Hilary Kramer as a new board member

**media[625348]**

SAN FRANCISCO, CALIFORNIA, March 04, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the ”œCompany”) ( GTBP), a clinical stage immuno-oncology company focused

**media[550143]**

SAN FRANCISCO, CALIFORNIA, Feb. 25, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the ”œCompany”) ( GTBP), a clinical stage immuno-oncology company focused

Israel-based Femto Technologies Inc. (FMTO) is up over 114 percent in Tuesday's pre-market trading. The following are some of the other stocks making big moves in Tuesday's pre-market trading.

SAN FRANCISCO, CALIFORNIA, Feb. 25, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the ”œCompany”) ( GTBP), a clinical stage immuno-oncology company focused

Initial data from the Phase 1 trial expected in 2025 SAN FRANCISCO, CALIFORNIA, Jan. 27, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the ”œCompany”) ( GT

GTBP Stock Hits 52-Week Low at $1.92 Amid Market Challenges

GT Biopharma Reports Third Quarter 2024 Financial Results

SAN FRANCISCO, CALIFORNIA, Sept. 26, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company...

GT Biopharma to Host Virtual KOL Event Showcasing its NK Cell Engager Pipeline and Broad Indication Potential on October 10, 2024

GTBP stock touches 52-week low at $1.92 amid market challenges

GTB-3650 TriKE® Phase 1 trial initiation expected in 2H 2024; initial clinical data expected in 1H 2025GTB-5550 TriKE® IND submission for treatment of B7H3...

GTBP stock touches 52-week low at $2.52 amid market challenges